Department of Health and Human Services, through National Institutes of Health, awarded Microbiotix, Inc. of Worcester, MA $599,327 under the STTR program (Phase I), with work starting 2025-09-22 and running to 2027-08-31. It is one of 2 SBIR and STTR awards Microbiotix, Inc. received in the last two years, $1,187,227 in all. Each figure links to the federal record.
The award
| Recipient | Microbiotix, Inc. (Worcester, MA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $599,327 |
| Period of performance starts | 2025-09-22 |
| Period of performance ends | 2027-08-31 |
| Award number | R41AI195240 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | Worcester, Worcester County, MA |
| Signed | 2025-09-20 |
| Recipient registry id (UEI) | SCNKBDM341T1 |
Want the whole picture on Microbiotix, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Microbiotix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Microbiotix, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
31 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Novel benzyl-piperidine antifungal agents to treat intractable mucorales infections - title: Novel benzyl-piperidine antifungal agents to treat intractable mucorales infections abstract. The fungal order mucorales [a who
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-25 | Continuation | 000 | $299,381 |
| 2025-09-20 | New | 000 | $299,946 |
Novel benzyl-piperidine antifungal agents to treat intractable mucorales infections - title: Novel benzyl-piperidine antifungal agents to treat intractable mucorales infections abstract. The fungal order mucorales [a who “high priority group” fungal pathogen] are the causative agents of mucormycosis, an aggressive, opportunistic mould infection that has devasting outcomes, with an overall mortality rate of ~50-60%. Mucormycosis primarily afflicts immunosuppressed patients. The progression of the disease is rapid. Once the infection has disseminated, IT is almost always fatal. Treatment options for mucormycosis are severely limited, as these fungi are intrinsically resistant to contemporary antifungals, including the echinocandins and most of the azoles. The antifungal agents in the development pipeline exhibit poor or no activity against mucorales, making the development of new, potent, and safe antifungals against mucorales remains an urgent, unmet need. To address this need, we identified a novel series of benzyl-piperidines (bps) that exhibit potent antifungal activity against pathogenic moulds. A representative bp, MBX-7591, exhibited potent antifungal activity against representative pathogens of the mucorales, such as rhizopus delemar and mucor lusitanicus, in in vitro susceptibility assays and in a murine model of acute invasive pulmonary mucormycosis. Based on these exci ...
From the federal award record.
Other SBIR and STTR awards to Microbiotix, Inc.
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-08-08 | Department of Health and Human Services | SBIR Phase I | $587,900 | Development of well tolerated novel inhibitors of drug resistant cmv - cmv occurs as a ben (record) |
Every other federal award to Microbiotix, Inc. on record
The federal register lists 29 or more other awards to the same registry id (UEI SCNKBDM341T1), $91,152,063 in all, from 2 agencies.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2025-08-01 | Defense Health Agency | $1,023,646 | Oxadiazole inhibitors of bacterial nonstop ribosome rescue for treating tick-borne diseases lyme and tularemia (HT94252510739) |
| 2025-02-01 | National Institutes of Health | $1,344,822 | Translational studies to advance filociclovir to ind submission for the treatment of adenoviral conjunctivitis (R33EY036947) |
| 2022-11-01 | National Institutes of Health | $8,795,790 | To develop the ppz series of small molecule pan-filovirus entry inhibitors through lead optimization, selectio (75N93023C00001) |
| 2022-08-12 | National Institutes of Health | $1,946,499 | Discovery of bunyaviral endonuclease inhibitors for anti viral - abstract segmented negative-sense, single-st (R42AI165102) |
| 2021-06-01 | National Institutes of Health | $1,462,324 | Development of filociclovir for the treatment of ocular adenoviral infections and keratoconjunctivitis - proje (R44EY032837) |
| 2020-07-01 | National Institutes of Health | $7,263,391 | To develop phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for mdr p. Aeruginos (75N93020C00019) |
| 2019-12-09 | National Institutes of Health | $600,000 | Discovery of enterovirus D68 2A protease inhibitors for antiviral therapy (R43AI149822) |
| 2019-09-01 | Defense Health Agency | $1,558,010 | Non-stop ribosome rescue inhibitors to treat mdr bacterial respiratory and skin infections (W81XWH1910426) |
| 2018-02-08 | National Institutes of Health | $600,000 | Synergistic panfiloviral entry inhibiting antibody drug conjugates (R43AI134598) |
| 2017-12-15 | Defense Contract Management Agency | $2,554,224 | Develop novel and innovative small molecule therapeutics to treat (post-exposure therapeutic) infections by bo (HDTRA118C0001) |
| 2017-08-18 | National Institutes of Health | $5,758,238 | Oxadiazole inhibitors of non-stop ribosome rescue to treat mdr neisseria gonorrhoeae (R01AI132276) |
| 2017-01-27 | National Institutes of Health | $2,974,481 | Screening for raav transduction enhancers - abstract recombinant adeno-associated virus (raav) is an establis (R44AI125043) |
| 2016-09-15 | Department of the Army | $1,155,860 | Novel thiazepinone plasmodial surface anion channel inhibitors as antimalarial drugs (W81XWH1620016) |
| 2016-08-19 | National Institutes of Health | $600,741 | T3SS needle protein inhibitors for the treatment of p. Aeruginosa infection (R41AI122433) |
| 2016-06-24 | National Institutes of Health | $601,809 | Novel beta-lactams as inhibitors of ebola virus infections (R43AI122465) |
| 2012-09-21 | National Institutes of Health | $4,307,667 | Novel plasmodial surface anion channel inhibitors as antimalarial drugs (R44AI100339) |
| 2012-04-03 | National Institutes of Health | $3,168,838 | Validating targets in p. Aeruginosa type iii secretion using chemical probes (R01AI099269) |
| 2012-03-15 | National Institutes of Health | $5,455,503 | Optimization of novel pyranopyridine efflux pump inhibitors (R44AI100332) |
| 2012-03-01 | National Institutes of Health | $5,966,463 | Novel spectinamide antibiotics for the treatment of mdr/xdr tuberculosis (R44AI098271) |
| 2010-07-01 | National Institutes of Health | $4,040,164 | Developing small molecule therapeutics for ebola hemorrhagic fever virus (R01AI089590) |
| 2009-09-01 | National Institutes of Health | $1,786,142 | DNA helicase and primase inhibitors for biodefense (R42AI064974) |
| 2009-07-01 | National Institutes of Health | $5,667,941 | Development of a novel lead series against category a & b bacterial pathogens (U01AI082052) |
| 2009-02-11 | National Institutes of Health | $2,990,305 | Novel methylenecyclopropane analogues as anti-human herpesvirus 6 and 8 agents (R44AI082799) |
| 2009-02-11 | National Institutes of Health | $633,573 | Novel methylenecyclopropane analogues as anti-human herpesvirus 6 and 8 agents (R43AI082799) |
| 2006-11-01 | National Institutes of Health | $2,945,791 | Identification of novel broad spectrum influenza virus inhibitors (R44AI072861) |
| 2006-09-15 | National Institutes of Health | $5,740,265 | Novel small molecule inhibitors of botulinum neurotoxin a (U01AI070430) |
| 2006-08-02 | Defense Contract Management Agency | $5,050,492 | Project funding (HDTRA106C0042) |
| 2006-08-01 | National Institutes of Health | $2,958,560 | Type iii secretion inhibitors for anti-infective therapy (R44AI068185) |
| 2003-06-01 | National Institutes of Health | $2,200,524 | A potent oral therapy for cytomegalovirus infection (R44AI054135) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Microbiotix, Inc.Look up Microbiotix, Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Microbiotix, Inc.Where this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.